Skip to content

Ending restenosis: Inhibition of vascular smooth muscle cell proliferation by cAMP

Research output: Contribution to journalArticle

Standard

Ending restenosis : Inhibition of vascular smooth muscle cell proliferation by cAMP. / Smith, Sarah A; Newby, Andrew C; Bond, Mark.

In: Cells, Vol. 8, No. 11, 1447, 16.11.2019.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Smith, Sarah A ; Newby, Andrew C ; Bond, Mark. / Ending restenosis : Inhibition of vascular smooth muscle cell proliferation by cAMP. In: Cells. 2019 ; Vol. 8, No. 11.

Bibtex

@article{2234bd7ec2f949438feecbd6bbac6293,
title = "Ending restenosis: Inhibition of vascular smooth muscle cell proliferation by cAMP",
abstract = "Increased vascular smooth muscle cell (VSMC) proliferation contributes towards restenosis after angioplasty, vein graft intimal thickening and atherogenesis. The second messenger 3’ 5’ cyclic adenosine monophosphate (cAMP) plays an important role in maintaining VSMC quiescence in healthy vessels and repressing VSMC proliferation during resolution of vascular injury. Although the anti-mitogenic properties of cAMP in VSMC have been recognised for many years, it is only recently that we have gained a detailed understanding of the underlying signalling mechanisms. Stimuli that elevate cAMP in VSMC inhibit G1-S phase cell cycle progression by inhibiting expression of cyclins and preventing S-Phase Kinase Associated Protein-2 (Skp2-mediated degradation of cyclin-dependent kinase inhibitors. Early studies implicated inhibition of MAPK signalling, although this does not fully explain the anti-mitogenic effects of cAMP. The cAMP effectors, PKA and EPAC act together to inhibit VSMC proliferation by inducing CREB activity and inhibiting members of the RhoGTPases, which results in remodelling of the actin-cytoskeleton. Cyclic-AMP induced actin remodelling controls proliferation by modulating the activity of Serum Response Factor (SRF) and TEA Domain Transcription Factors (TEAD), which regulate expression of genes required for proliferation. Here we review recent research characterising these mechanisms, highlighting novel drug targets that may allow the anti-mitogenic properties of cAMP to be harnessed therapeutically to limit restenosis.",
keywords = "cAMP, VSMC, PROLIFERATION, cell-cycle, actin, cytoskeleton, SRF, TEAD, CREB",
author = "Smith, {Sarah A} and Newby, {Andrew C} and Mark Bond",
year = "2019",
month = "11",
day = "16",
doi = "10.3390/cells8111447",
language = "English",
volume = "8",
journal = "Cells",
issn = "2073-4409",
publisher = "MDPI AG",
number = "11",

}

RIS - suitable for import to EndNote

TY - JOUR

T1 - Ending restenosis

T2 - Inhibition of vascular smooth muscle cell proliferation by cAMP

AU - Smith, Sarah A

AU - Newby, Andrew C

AU - Bond, Mark

PY - 2019/11/16

Y1 - 2019/11/16

N2 - Increased vascular smooth muscle cell (VSMC) proliferation contributes towards restenosis after angioplasty, vein graft intimal thickening and atherogenesis. The second messenger 3’ 5’ cyclic adenosine monophosphate (cAMP) plays an important role in maintaining VSMC quiescence in healthy vessels and repressing VSMC proliferation during resolution of vascular injury. Although the anti-mitogenic properties of cAMP in VSMC have been recognised for many years, it is only recently that we have gained a detailed understanding of the underlying signalling mechanisms. Stimuli that elevate cAMP in VSMC inhibit G1-S phase cell cycle progression by inhibiting expression of cyclins and preventing S-Phase Kinase Associated Protein-2 (Skp2-mediated degradation of cyclin-dependent kinase inhibitors. Early studies implicated inhibition of MAPK signalling, although this does not fully explain the anti-mitogenic effects of cAMP. The cAMP effectors, PKA and EPAC act together to inhibit VSMC proliferation by inducing CREB activity and inhibiting members of the RhoGTPases, which results in remodelling of the actin-cytoskeleton. Cyclic-AMP induced actin remodelling controls proliferation by modulating the activity of Serum Response Factor (SRF) and TEA Domain Transcription Factors (TEAD), which regulate expression of genes required for proliferation. Here we review recent research characterising these mechanisms, highlighting novel drug targets that may allow the anti-mitogenic properties of cAMP to be harnessed therapeutically to limit restenosis.

AB - Increased vascular smooth muscle cell (VSMC) proliferation contributes towards restenosis after angioplasty, vein graft intimal thickening and atherogenesis. The second messenger 3’ 5’ cyclic adenosine monophosphate (cAMP) plays an important role in maintaining VSMC quiescence in healthy vessels and repressing VSMC proliferation during resolution of vascular injury. Although the anti-mitogenic properties of cAMP in VSMC have been recognised for many years, it is only recently that we have gained a detailed understanding of the underlying signalling mechanisms. Stimuli that elevate cAMP in VSMC inhibit G1-S phase cell cycle progression by inhibiting expression of cyclins and preventing S-Phase Kinase Associated Protein-2 (Skp2-mediated degradation of cyclin-dependent kinase inhibitors. Early studies implicated inhibition of MAPK signalling, although this does not fully explain the anti-mitogenic effects of cAMP. The cAMP effectors, PKA and EPAC act together to inhibit VSMC proliferation by inducing CREB activity and inhibiting members of the RhoGTPases, which results in remodelling of the actin-cytoskeleton. Cyclic-AMP induced actin remodelling controls proliferation by modulating the activity of Serum Response Factor (SRF) and TEA Domain Transcription Factors (TEAD), which regulate expression of genes required for proliferation. Here we review recent research characterising these mechanisms, highlighting novel drug targets that may allow the anti-mitogenic properties of cAMP to be harnessed therapeutically to limit restenosis.

KW - cAMP

KW - VSMC

KW - PROLIFERATION

KW - cell-cycle

KW - actin

KW - cytoskeleton

KW - SRF

KW - TEAD

KW - CREB

U2 - 10.3390/cells8111447

DO - 10.3390/cells8111447

M3 - Article

VL - 8

JO - Cells

JF - Cells

SN - 2073-4409

IS - 11

M1 - 1447

ER -